Verteporfin liposome
Liposomal verteporfin is a liposome-encapsulated form of Verteporfin (HY-B0146). Verteporfin is a photosensitizer used in photodynamic therapy, which generates reactive oxygen species (ROS) upon irradiation at 690 nm to mediate photodynamic effects. Liposomal verteporfin can promote the release of Oxaliplatin (HY-17371) from endolysosomes via photochemical internalization (PCI), prolong the drug circulation time and enable sustained release, accumulate the drug in neovascular vessels, and enhance its cytotoxicity in tumor models. Liposomal verteporfin can be used in studies related to neovascular eye diseases and pancreatic cancer[1][2][3].
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All YAP Isoforms
More
Biological Activity
Description
In Vitro
Verteporfin liposome (0.01-0.8 μM; 1 h) exhibits extremely low dark toxicity in MIA PaCa-2 and PANC-1 pancreatic cancer cells, and induces concentration-dependent cytotoxicity after irradiation with 0.5 J/cm2[1].
Verteporfin liposome (25-250 μM; 0.5-24 h) is taken up by MIA PaCa-2 and PANC-1 3D microtumors in a time-dependent manner[1].
Photodynamic therapy (PDT) with Verteporfin liposome (100 μM; 8 h) synergizes with Oxaliplatin (HY-17371) to reduce the viability of 3D pancreatic cancer microtumors of MIA PaCa-2 and PANC-1[1].
Verteporfin liposomes are taken up faster by LDL receptor-enriched human colon cancer cell lines than aqueous sodium hematoporphyrin[3].
Strong lysosomal colocalization is observed in MIA PaCa-2 and PANC-1 pancreatic cancer cells treated with Verteporfin liposome (200 μM; 2, 8, 24 h)[1].
The binding rate of Verteporfin liposome to plasma lipoproteins in vitro reaches up to 91%, with a balanced distribution among major lipoprotein fractions[3].
Verteporfin liposomes are selectively taken up by LDL receptor-positive cell lines in vitro via LDL receptor-mediated binding[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MIA PaCa-2, PANC-1
-
Concentration:200 μM
-
Incubation Time:2, 8, 24 h
-
Result:Showed strong colocalization with lysosomes after 8 hours of incubation, with average Pearson’s correlation coefficients of 0.8 in both cell lines.
Maintained high colocalization coefficients across all time points for NLBPD and FLBPD, while CLBPD showed a decrease in colocalization at 24 hours in both cell lines.
Exhibited fluorescence across cellular membranes, indicating non-exclusive lysosomal localization.
-
Cell Line:MIA PaCa-2, PANC-1 3D microtumor cultures
-
Concentration:25, 50, 100, 200, 250 μM (dark toxicity); 100 μM (uptake kinetics)
-
Incubation Time:24 h (dark toxicity); 30 minutes, 1, 2, 4, 8, 16, 24 h (uptake kinetics)
-
Result:Increased in uptake over time, with maximal uptake observed at 24 hours.
Showed the highest uptake for CLBPD in PANC-1 microtumors.
Demonstrated non-toxicity at 100 μM to microtumors.
-
Cell Line:MIA PaCa-2, PANC-1 3D microtumor cultures
-
Concentration:100 μM
-
Incubation Time:8 h
-
Result:Reduced MIA PaCa-2 microtumor viability to 55%, 59%, and 50% respectively for NLBPD, FLBPD, or CLBPD monotherapy.
Reduced MIA PaCa-2 microtumor viability to 20% when combining FLBPD PDT with oxaliplatin, a significant decrease compared to monotherapies.
Achieved a global synergy score of 29.41 for MIA PaCa-2, with radiant exposures ≥2.5 J/cm2 synergistic with all oxaliplatin doses.
Maintained PANC-1 microtumor viability at 71%, 68%, and 74% respectively for NLBPD, FLBPD, or CLBPD monotherapy.
Reduced PANC-1 microtumor viability to 45%, 56%, and 56% respectively when combining NLBPD, FLBPD, or CLBPD PDT with oxaliplatin.
Achieved a global synergy score of 8.75 for PANC-1, with synergy observed at select dose combinations.
Diminished combination treatment efficacy in both cell lines when dynasore was added.
In Vivo
Verteporfin liposome (intravenous injection; single dose) achieves higher tumor tissue concentrations in tumor-bearing mice with abundant LDL receptors than water-soluble Verteporfin (HY-B0146)[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Rj: NMRI-Foxn1nu/nu nude mice (female, 6 weeks old, orthotopic implantation of luciferase-expressing PANC-1 cells)[1]
-
Dosage:0.5 mg/kg (liposomal verteporfin); 5 mg/kg (oxaliplatin)
-
Administration:i.p. (liposomal verteporfin, followed by 690 nm light irradiation at 150 mW/cm2 for 50 J/cm2); i.p. (oxaliplatin, immediate post-irradiation)
-
Result:Achieved the lowest tumor volumes and heterogeneity compared to monotherapies or sham treatment.
Showed 58% of mice had tumor response, with mean bioluminescence signal reduction significantly greater than oxaliplatin monotherapy and near-significantly greater than PDT monotherapy.
Maintained stable body weight profiles confirming tolerability.
Chemical Information
-
SMILES
[Verteporfin liposome]
-
Synonyms
Liposomal verteporfin
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Verteporfin liposome
- Liposomal verteporfin
- Liposome
- YAP
- Reactive Oxygen Species (ROS)
- age-related macular degeneration
- MIA PaCa-2
- PANC-1
- pancreatic ductal adenocarcinoma
- pancreatic cancer cells
- LDL receptor
- subfoveal choroidal neovascularisation
- pathological myopia
- orthotopic pancreatic tumors
- presumed ocular histoplasmosis syndrome
- Inhibitor
- inhibitor
- inhibit